A comparative efficacy trial in germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the lederle whole-cell component DTP vaccine, or DT vaccine

Pediatrics

Volumn 101, Issue 1 I, 1998, Pages 1-11

  Stehr, Klemens ^a,b   Cherry, James D ^b   Heininger, Ulrich ^a   Schmitt Grohé, Sabina ^a   Überall, Michael ^a   Laussucq, Suzanne ^c   Eckhardt, Thomas ^c   Meyer, Martin ^d   Engelhardt, Rita ^b   Christenson, Peter ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Acellular pertussis vaccine; B parapertussis; B pertussis; Double blind; Whole cell pertussis vaccine

Indexed keywords

DIPHTHERIA TETANUS TOXOID; DIPHTHERIA TETANUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS VACCINE;

ANOREXIA; ARTICLE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FOLLOW UP; GERMANY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PERTUSSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BORDETELLA INFECTIONS; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; POLYMERASE CHAIN REACTION; WHOOPING COUGH;

EID: 6844258864     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.101.1.1     Document Type: Article

References (51)

1. Lewis K, Cherry JD, Baraff LJ, et al. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children. Proceedings of the Fourth International Symposium on Pertussis; Joint IABS/ SHO Meeting; Geneva, Switzerland, 1984. 1985;61:563-569
2. Lewis K, Cherry JD, Holroyd HJ, Baker LR, Dudenhoeffer FE, Robinson RG. A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. Am J Dis Child. 1986;140:872-876
3. Edwards KM, Lawrence E, Wright PF. Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components. Am J Dis Child. 1986;140:867-871
4. Anderson EL, Belshe RB, Bartram J, et al. Clincial and serologic responses to acellular pertussis vaccine in infants and young children. Am J Dis Child. 1987;141:949-953
5. Pichichero ME, Badgett JT, Rodgers GC, et al. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs a whole-cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18 to 24 month old children. Pediatr Infect Dis. 1987;6: 352-363
6. Anderson El, Belshe RB, Bartram J. Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis. 1988;157:731-736
7. Morgan CM, Blumberg DA, Cherry JD, et al. Comparison of acellular and whole-cell pertussis components DTP vaccines; a multicenter double-blind study in 4 to 6 year-old children. Am J Dis Child. 1990;144: 41-45
8. Blumberg DA, Mink CM, Cherry JD, et al. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17-to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J Pediatr. 1990;117:46-51
9. Blumberg DA, Mink CM, Cherry JD, et al. Comparison of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. J Pediatr. 1991;119:194-204
10. Blumberg DA, Chatfield PC, Cherry JD, et al. Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine. Vaccine. 1992;10:614-616
11. Cherry JD, Mortimer EA, Hackell JG and the Multicenter APDT Vaccine Study Groups. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda Acellular Pertussis-Diphtheria-Tetanus (APDT) vaccines. Develop Biol Standard. 1991;73:51-58
12. Stehr K, Lugauer S, Heininger U, Uhlenbusch R, Cherry JD. Verträglichkeit und Immunogenität der Keuchhustenimpfung mit einem azellulären monovalenten 4-Komponenten-Impfstoff (Lederle/ Takeda) bei 185 Erwachsenen. (English translation: Reactogenicity and immunogenicity of pertussis immunization with a 4-component acellular vaccine (Lederle/Takeda) in 185 adults.) Pädiatr Grenzgeb. 1995;34: 219-223
13. Edwards KM, Decker MD, Graham BS, Mezzatesta J, Scott J, Hackell J. Adult immunization with acellular pertussis vaccine. JAAM. 1993;269: 53-56
14. Kimura M, Kuno-Sakai H, Sato Y, et al. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Am J Dis Child. 1991;145:734-741
15. Kamiya H, Ritsue N, Matsuda T, Yasuda N, Christenson PD, Cherry JD. Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in two and three month old children in Japan. Am J Dis Child. 1992;146:1141-1147
16. Heininger U, Cherry JD, Christenson P, et al. Comparative study of Lederle/Takeda acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine. 1994;12: 81-86
17. Glode M, Joffe L, Reisinger K, et al. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17-to 24-month-old children. Pediatr Infect Dis J. 1992;11:530-535
18. Watson B, Cawein A, McKee BL and Hackell JG. Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four-and six-month-old infants. Pediatr Infect Dis J. 1992;11:930-935
19. Rothstein EP, Bernstein HH, Glode MP, et al. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines. Am J Dis Child. 1993;147:854-857
20. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96: 548-557
21. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of thirteen acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96: 557-566
22. Mortimer EA, Kimura M, Cherry JD, et al. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child. 1990;144:899-904
23. Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use - supplementary ACIP statement. MMWR. 1992;41:1-10
24. Centers for Disease Control. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR-7):1-25
25. Stehr K. Pertussisschutzimpfung. In: Spiess H, ed. Impfkompendium. 4th ed. New York, NY: Georg Thieme Verlag Stuttgart; 1994:143-159
26. Stehr K, Heininger U. Aktueller Stand der Keuchhustenschutzimpfung, Pädiat Prax. 1991;42:391-402
27. Finger H, Wirsing von König CH, Tacken A, Wassilak SGF. The epidemiological situation of pertussis in the Federal Republic of Germany. Develop Biol Standard. 1991;73:343-355
28. Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J. 1993;12: 504-509
29. Schläpfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis J. 1995;14:209-214
30. Manclark CR, Meade BD, Burstyn DG. Serologic response to Bordetella pertussis. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:388-394
31. World Health Organization. WHO Meeting on Case Definition of Pertussis: Geneva. January 10-11, 1991. Geneva, Switzerland: World Health Organization; 1991:4-5 (Issue no. MIN/EPI/PERT/91.1)
32. Storsaeter J, Olin P. Relative efficacy of two acellular pertussis vaccinees during three years of passive surveillance. Vaccine. 1992;10:142-144
33. Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines - efficacy and evaluation of clinical case definitions. Am J Dis Child. 1991;145:1285-1289
34. Stehr K, Cherry JD. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine. Develop Biol Standard. 1997;89:58-62
35. Kalbfleisch JD, Pren KL. The Statisical Analysis of Failure Time Data. New York, NY: John Wiley; 1980
36. Schmitt-Grohé S, Stehr K, Cherry JD, et al. Minor adverse events in a comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Develop Biol Standard. 1997;89:113-118
37. Überall MA, Stehr K, Cherry JD, et al. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Develop Biol Standard. 1997;89:83-89
38. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med. 1996;334:349-355
39. Trollfors B, Taranger J, Lagergard T. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med. 1995;333:1045-1050
40. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275:37-41
41. Greco D, Salmaso S, Mastrantonio P. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341-348
42. Taranger J, Trollfors B, Lagergard T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J. 1997;16:180-184
43. Trollfors B, Taranger J, Lagergard T, et al. Efficacy of a monocomponent pertussis-toxoid vaccine after household exposure to pertussis. J Pediatr. 1997;130:532-536
44. Heininger U, Stehr K, Schmitt-Grohé S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J. 1994;13:306-309
45. Hausman S, Cherry JD, Heininger U, Wirsing von König CH, Burns DL. Analysis of proteins encoded by the ptx and ptl genes of Bordetella bronchiseptica and Bordetella parapertussis. Infect Immunol. 1996;64: 4020-4026
46. Iwata S, Aoyama T, Goto A, et al. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis in an apartment house. Develop Biol Standard. 1991;73:333-341
47. Linnemann CC, Perry EB. Bordetella parapertussis. Recent experience and a review of the literature. Am J Dis Child. 1977;131:560-563
48. Lautrop H. Observations on parapertussis in Denmark 1950-1957. Acta Pathol Microbiol Scand. 1958;43:255-266
49. Khelef N, Danve B, Quentin-Millet MJ, Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immunol. 1993;61:486-490
50. Edwards KM, Decker MD, Halsey NA, Koblin BA, Townsend T, Auerbach B, Karzon DT. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics. 1991;88:1019-1023
51. Cherry JD. Strategies for diphtheria, tetanus, and pertussis (DTP) immunization. Report of the 104th Ross Conference on Pediatric Research, Strategies for Pediatric Vaccines: Conventional and Molecular Approaches, 13; Columbus, OH; Ross Products Division, Abbott Laboratories; 1994:218-225